Tumours with low glucometabolic levels may benefit from anti-CTLA-4 therapy; hence, a combination of anti-CTLA-4 and anti-PD1/PD-L1 therapies may have a synergistic effect in the treatment of advanced malignancies [9]. Here, CTLA4 is linked to neoplasm.